These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33716055)

  • 1. Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis.
    Hughes DM; DeMari S; Hassan H; Sanchorawala V; Sloan JM
    Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e460-e463. PubMed ID: 33716055
    [No Abstract]   [Full Text] [Related]  

  • 2. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
    Wei XX; Siegel AP; Aggarwal R; Lin AM; Friedlander TW; Fong L; Kim W; Louttit M; Chang E; Zhang L; Ryan CJ
    Oncologist; 2018 Jun; 23(6):656-e64. PubMed ID: 29487219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
    Magen H; Geva M; Volchik Y; Avigdor A; Nagler A
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e947-e955. PubMed ID: 32868229
    [No Abstract]   [Full Text] [Related]  

  • 4. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.
    Chari A; Vogl DT; Jagannath S; Jasielec J; Unger TJ; DeCastro A; Shah J; Kauffman M; Shacham S; Jakubowiak A
    Br J Haematol; 2020 May; 189(4):e126-e130. PubMed ID: 32124443
    [No Abstract]   [Full Text] [Related]  

  • 5. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
    Mouhieddine TH; Parekh S; Cho HJ; Richter J; DeCastro A; Shah J; Landesman Y; Chari A; Jagannath S; Madduri D
    Ann Hematol; 2021 Dec; 100(12):3057-3060. PubMed ID: 33009581
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
    Salcedo M; Lendvai N; Mastey D; Schlossman J; Hultcrantz M; Korde N; Mailankody S; Lesokhin A; Hassoun H; Smith E; Shah U; Diab V; Werner K; Landau H; Lahoud O; Drullinsky P; Shah G; Chung D; Scordo M; Giralt S; Landgren O
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):198-200. PubMed ID: 32001193
    [No Abstract]   [Full Text] [Related]  

  • 7. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
    Peterson TJ; Orozco J; Buege M
    Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
    Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M; Savoie L; Trudel S; Areethamsirikul N; Unger TJ; Rashal T; Hanke T; Kauffman M; Shacham S; Reece D
    Blood; 2018 Feb; 131(8):855-863. PubMed ID: 29203585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
    Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma.
    Chakraborty R; Efficace F
    Br J Haematol; 2020 May; 189(3):e112-e113. PubMed ID: 32080829
    [No Abstract]   [Full Text] [Related]  

  • 11. Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
    Richard S; Richter J; Jagannath S
    Future Oncol; 2020 Jul; 16(19):1331-1350. PubMed ID: 32511022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
    Shah J; Shacham S; Kauffman M; Daniele P; Tomaras D; Tremblay G; Casasnovas RO; Maerevoet M; Zijlstra J; Follows G; P Vermaat JS; Kalakonda N; Goy AH; Choquet S; Den Neste EV; Hill BT; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Bouabdallah R; Jäger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vasilakopoulos TP; Samal P; Nagy A; Ku M; Canales Albendea MÁ
    Future Oncol; 2021 Apr; 17(11):1295-1310. PubMed ID: 33528286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
    Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
    Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
    Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
    Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
    Kastritis E; Gavriatopoulou M; Roussou M; Bagratuni T; Migkou M; Fotiou D; Ziogas DC; Kanellias N; Eleutherakis-Papaiakovou E; Dialoupi I; Ntanasis-Stathopoulos I; Spyropoulou-Vlachou M; Psimenou E; Gakiopoulou H; Marinaki S; Papadopoulou E; Ntalianis A; Terpos E; Dimopoulos MA
    Amyloid; 2018 Dec; 25(4):234-241. PubMed ID: 30663408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
    Khwaja J; Bomsztyk J; Atta M; Bygrave C; Forbes A; Durairaj S; Fernandes S; Taylor J; Paterson P; Brearton G; Crawley C; Sheehy O; Brown R; Soutar R; Garg M; Rydzewski A; Jamroziak K; Mahmood S; Wechalekar AD
    Br J Haematol; 2024 May; 204(5):1811-1815. PubMed ID: 38171355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selinexor: First Global Approval.
    Syed YY
    Drugs; 2019 Sep; 79(13):1485-1494. PubMed ID: 31429063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacist's review of the treatment of systemic light chain amyloidosis.
    Hughes DM; Staron A; Sanchorawala V
    J Oncol Pharm Pract; 2021 Jan; 27(1):187-198. PubMed ID: 33028132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.